Vaxxitek HVT+IBD (--) - Suspension and solvent for suspension for injection

Authorised

- Turkey herpesvirus, strain vHVT013-69 (cell-associated), expressing VP2 protein gene of Infectious bursal disease virus (strain Faragher 52/70), Live

Product identification

Medicine name:
Vaxxitek HVT+IBD (--) - Suspension and solvent for suspension for injection

Active substance:
Turkey herpesvirus, strain vHVT013-69 (cell-associated), expressing VP2 protein gene of Infectious bursal disease virus (strain Faragher 52/70), Live

Target species:
Chicken
Chicken (embryonated eggs)

Route of administration:
In ovo
Subcutaneous use

Product details

Active substance and strength:

Turkey herpesvirus, strain vHVT013-69 (cell-associated), expressing VP2 protein gene of Infectious bursal disease virus (strain Faragher 52/70), Live

Presentation_strength:at least 3.6 log to 4.4 log10 PFU Reference:Hse Index:0

Pharmaceutical form:

Suspension and solvent for suspension for injection

Withdrawal period by route of administration:

In ovo:

- **Chicken**
  - Not applicable. 0 day Zero days

Subcutaneous use:

- **Chicken**
  - Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI01AD15

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:
Belgium , France , Hungary , Luxembourg , Poland , Spain

Package description:
Packaging:Ampoule (glass), Package_size:1 ampoule, Content:2000 doses
Packaging:Ampoule (glass), Package_size:1 ampoule, Content:1000 doses

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Complete application (stand-alone) - Council Directive 81/851/EEC

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:
9/08/2002

Manufacturing sites for batch release:
Laboratoire Bioluz
Boehringer Ingelheim Animal Health France

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
27/04/2010

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 5/03/2025
Download